← All trials
NCT04975698
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2021
- Primary completion
- Jun 30, 2025
- Completion date
- Jun 30, 2026
- First posted
- Jul 23, 2021
- Last posted
- Nov 5, 2021
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- National Cancer Institute (NCI)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Sponsor investigator
- National Marrow Donor ProgramCollaborator
- National Marrow Donor ProgramStudy chair
- Georgetown UniversityCollaborator
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.